# Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma

> **NCT06463522** · PHASE1,PHASE2 · RECRUITING · sponsor: **Beijing 302 Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** Autologous Tumor-infiltrating Lymphocytes

## Key facts

- **NCT ID:** NCT06463522
- **Lead sponsor:** Beijing 302 Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-07-01
- **Final completion:** 2026-07-01
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2024-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06463522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06463522, "Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes Therapy in Patients With Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06463522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*